DSCSA’s Next Big Hurdle

Published on: 
BioPharm International, BioPharm International, Regulatory Sourcebook March 2022, Volume 2022 eBook, Issue 1
Pages: 30-32

Interoperability by 2023 depends on data standardization and systems compatibility between trading partners.

The 2023 final deadline for full US FDA Drug Supply Chain Security Act (DSCSA) unit level interoperable traceability is looming. By now, most pharmaceutical manufacturers are properly barcoding products to meet current DSCSA-specified labeling requirements for unique product identification at the lot level. The barcodes contain digitized product data that will be used to improve patient safety by enabling major improvements in the track-and-traceability of drugs as they move through the supply chain.

Now it’s time for companies to begin exchanging the necessary data to ensure readiness for November 2023. Establishing interoperability between all stakeholders up and down the supply chain is a complex undertaking—it will take every bit of time that remains before the deadline.

Read this article in BioPharm International's March 2022 Quality and Regulatory Sourcebook eBook.

About the author


Tracy Nasarenko is senior director Community Engagement, GS1 US.

Article Details

BioPharm International eBook: Quality and Regulatory Sourcebook, March 2022 Pages: 30-32


When referring to this article, please cite it as T. Nasarenko, “DSCSA's Next Big Hurdle," BioPharm International Quality and Regulatory Sourcebook eBook (March 2022).